

ASX Announcement

Medibio Limited – 15 February 2023



Medibio Appoints Non-Executive Director to the Board

Melbourne, Australia and Minneapolis, MN – 15 February 2023: Medibio Limited (“MEB” or “Medibio”) (ASX: MEB) (OTCPINK: MDBIF) is pleased to welcome Mr Christopher Ntoumenopoulos to its Board of Directors as Non-Executive Director with immediate effect.

Chris Ntoumenopoulos comes to Medibio with over 20 years of experience in financial markets in both capital raising and corporate strategy. He serves as the Managing Director at Twenty 1 Corporate, an Australian-based corporate advisory firm that provides funding and corporate support for innovative companies and technologies. He is currently a Director of Tryp Therapeutics in Canada.

Ntoumenopoulos served as a founding director of Race Oncology (RAC) and ResApp Health (RAP), which Pfizer acquired in 2022.

Mr Ntoumenopoulos holds a Bachelor of Commerce degree from the University of Western Australia, focusing on Money and Banking, Investment Finance, and Electronic Commerce.

The Board is excited to have Mr Ntoumenopoulos join the Board who brings extensive experience to the Company.

– ENDS –

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited.

For Further information:

David Trimboli
Non-Executive Chair
T: +61 3 9692 7222

About Medibio Limited

Medibio (ASX: MEB) (OTCPINK: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTC Pink Open Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.